Sight Sciences Stock News

Sight Sciences (NASDAQ:SGHT) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued on Saturday, Zacks.com reports. According to Zacks, Sight Sciences Inc. is a medical device company. It focused on the development and commercialization of proprietary devises which target the underlying causes of prevalent eye []

Sight Sciences Inc. (SGHT) CEO Paul Badawi on Q3 2021 Results - Earnings Call Transcript

The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionabl

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market clo

On Thursday, Sight Sciences Inc. (NASDAQ:SGHT) shares rallied more than 12% after reporting positive TearCare data. SGHT is exploring how TearCare could be used for localized heat therapy in adult pat

Sight Sciences Seeks Injunction Related to Hydrus® Microstent's Infringement Sight Sciences Seeks Injunction Related to Hydrus® Microstent's Infringement

MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address

Sight Sciences, Inc. (SGHT) CEO Paul Badawi on Q2 2021 Results - Earnings Call Transcript

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursd

New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented New safety and efficacy data fro

MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target th

Sight Sciences has two innovative products to address eye diseases. Commercial traction is good, from a low sales base, as the potential is large.

MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target th

Sight Sciences Inc. is now set to go public at a valuation of more than $1 billion, after the expected pricing and number of shares to be offered in the California-based ophthalmology and optometry co

Sight Sciences has filed to raise $150 million in an IPO. The firm is developing and commercializing medical device treatments for glaucoma and dry eye disease.